Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Inserm · Centre Hospitalier Universitaire de Bordeaux · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,534
total citations
- FWCI
- 57.76
- Percentile
- 100%
- References
- 29
Citations per year
Authors
13- FMFrançois‐Xavier MahonCorresponding
Inserm, Centre Hospitalier Universitaire de Bordeaux, Bordeaux Population Health
- DRDelphine Réa
Hôpital Saint-Louis
- JGJoëlle Guilhot
Inserm, Centre Hospitalier Universitaire de Poitiers
- FGFrançois Guilhot
Centre Hospitalier Universitaire de Poitiers, Inserm
- FHFrançoise Huguet
Hôpital Purpan
Topics & keywords
Topics
Keywords
- Medicine
- Imatinib
- Discontinuation
- Internal medicine
- Imatinib mesylate
- Interim analysis
- Prospective cohort study
- Surgery
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.